Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114775 · ClinicalTrials.gov registry record · Phase 1
Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)
A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02114775 is a Phase 1 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 34 participants.
The verdict
NCT02114775, a Phase 1 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The overall goal is to determine whether perceptual or performance fatigue can be reduced in MTBI patients with and without growth hormone (GH) deficiency by treating them in a crossover fashion based upon GH status. A battery of functional, fatigue, cognitive, imaging and blood flow tests will be performed to assess the efficacy of the two drug interventions, Growth hormone and Sildenafil.
Interventions
- DRUG Placebo
- DRUG Sildenafil
- DRUG Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-12-12 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02114775
The ClinicalTrials.gov registry entry for NCT02114775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02114775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02114775 about?
NCT02114775 is a clinical study titled "Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)". The overall goal is to determine whether perceptual or performance fatigue can be reduced in MTBI patients with and without growth hormone (GH) deficiency by treating them in a crossover fashion based upon GH status. A battery of functional, fatigue, cognitive, imaging and blood flow tests will be ...
What is the current status of trial NCT02114775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2014-12-12. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02114775?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG), Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT02114775?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.